COMMUNIQUÉS West-GlobeNewswire

BrightInsight Recognized Among Newsweek’s World’s Best Digital Health Companies 2024 List
24/04/2024
SAN JOSE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- BrightInsight, Inc . , the trusted partner and de-facto platform driving value for top biopharma compliant digital health solutions, is thrilled to announce it has [...]
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
24/04/2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
NMDP to Present New Stem Cell Transplantation Data at the 2024 American Society of Clinical Oncology Annual Meeting
24/04/2024
MINNEAPOLIS, April 24, 2024 (GLOBE NEWSWIRE) -- NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR ® (Center for International Blood and Marrow Transplant Research ® ) will present new data on hematopoietic [...]
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024
24/04/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET, where ALK’s [...]
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
24/04/2024
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- [...]
Global COVID-19 Memorial Will Honor Pandemic Frontline & Essential Workers
24/04/2024
CHICAGO, April 24, 2024 (GLOBE NEWSWIRE) -- A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in [...]
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the [...]
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
24/04/2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its [...]
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
24/04/2024
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo ® ( [...]
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
24/04/2024
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external [...]
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc [...]
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 [...]
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24/04/2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells [...]
ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at Upcoming Medical Conferences
24/04/2024
Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic ductal adenocarcinoma ( [...]
Immunocore announces upcoming presentation and posters at ASCO 2024
24/04/2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral [...]
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
24/04/2024
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial [...]
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
24/04/2024
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune [...]
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24/04/2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC - IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: [...]
Clearday introduces digital assistants in residential communities
24/04/2024
San Antonio, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Clearday (OTCQX CLRD) is pleased to announce its new line of digital assistants for use in residential communities and the Clearday Clubs. Digital assistants can [...]

Pages